In 2026, digital advertising spend in the pharmaceutical sector officially crossed a line that had been forecast for a decade: it surpassed linear television for the first time. According to the 2026 MM+M/Inmar Healthcare Marketers Trend Report, the overall healthcare marketing and communications market has grown to an estimated $26.52 billion this year, up from $24.55 billion in 2025, with digital video and display leading all channels on a projected 70% year-over-year budget increase.
The milestone is real. The map it implies is not.
Reallocating a budget is a spreadsheet exercise. Building the data infrastructure, attribution models and cross-functional workflows that make those digital dollars accountable is something else entirely. That gap — between where the money went and whether the organizations spending it can prove it worked — is the actual story of digital marketing in 2026.
The question marketers face is no longer whether shifting budgets from linear TV to connected TV makes sense. It is whether teams can demonstrate, on a weekly basis, what the reallocation has produced. Most cannot answer that in the form their CFOs want.
Consider what that looks like in practice. A pharmaceutical brand team asked why the digital line item grew 70%, and what the company received in return, can produce dashboards without difficulty: impressions, video completion rates, engagement scores, cost per thousand across a dozen platforms. What it cannot produce, without heavy caveats, is a defensible line connecting those numbers to prescriptions written, patients retained, or revenue booked. The spend moved. The measurement did not move with it.
That gap is not a failure of ambition. It is a failure of sequencing. And it has been widened, sharply, by a single structural change in how audiences now find information.
That change is the collapse of search as it was previously understood. The 2026 guide to legal marketing in Canada, published by Marketing News Canada and written by Darian Kovacs, principal at Jelly Digital Marketing & PR, describes AI Overviews, SearchGPT, Gemini and Perplexity as answer-focused tools displacing the traditional list of search results — with firms no longer competing to rank, but competing to be cited. Generative Engine Optimization, as the industry has started calling it, requires content that is machine-readable, authoritatively sourced and packed with original data the language models can lift and attribute.
The pattern is playing out across industries, and healthcare is feeling it acutely. Pharmaceutical brands with websites that held top-three organic rankings for regional queries about conditions, treatments and clinical trials report traffic eroding without obvious algorithm updates. When those same queries run through major AI assistants, the traditional top-rankers are often absent from the summaries entirely. The AI is citing competitors whose content is structured as direct question-and-answer pairs with condition-specific statistics. The lesson is uncomfortable and simple: ranking on Google no longer guarantees visibility in the interface where patients and physicians now start.
This is where the capability gap becomes visible. A brand team that reallocates budget toward answer-engine optimization is making the right strategic move. But the traffic that once arrived through a blue link — traceable, tagged, attributable to a specific campaign — now arrives, if it arrives at all, through a cited mention inside an AI-generated summary the marketer cannot instrument. The channel changed. The measurement stack did not.
That produces the reckoning with attribution that is the second half of this year’s story. For years, the marketing mix model was the industry’s instrument of record. The six-month marketing mix analysis is giving way to AI-driven dashboards that provide daily directional guidance rather than post-mortem verdicts, but the underlying signals those dashboards depend on are precisely the signals that answer-engine intermediation degrades.
The days of measuring back only to clicks or impressions or reach and frequency are over. Measurement now needs to connect not only to scripts, but to patient intent, adherence — whatever it is that the brand is ultimately trying to achieve. The problem is that measurement models disagree with one another more than most marketers admit. The same campaign can produce wildly different ROI figures depending on the attribution model applied. That is not a temporary glitch. It is the new baseline, and it is the baseline the CFO is being asked to fund against.
There are complications worth naming plainly. Traffic quality is deteriorating across the open web as bot activity climbs; the disconnect between reported impressions and actual human attention has widened enough that machine-generated pageviews continue slipping past standard analytics filters. Privacy regulation is tightening in ways that affect data collection and cross-border transfers, particularly for brands operating in or advertising into markets with strict consent, storage and data-localization regimes. Each of these complications makes the attribution problem harder, not easier, at exactly the moment budgets are betting on measurement improving.
Inside large healthcare marketers, the sequence this year has tended to run the same way. A team spends a year restructuring its content library into question-and-answer pairs, seeding original data into the abstracts and repositories the language models are known to ingest, and watching its brand begin to appear in AI-generated summaries for the conditions it treats. Share of citation — an internal metric invented for the purpose, because no standard one exists — climbs quarter over quarter.
Then leadership asks for ROI.
The team can show the citations. It can show that traffic to the brand site stabilized rather than collapsed, which competitors cannot claim. What it cannot show, with any confidence, is whether a physician who encountered the brand inside an AI summary went on to write a prescription, request a rep visit, or do nothing at all. The old attribution chain — search click, site visit, HCP portal registration, rep follow-up, script — has been severed at the top. The new chain has not been built. The reasonable question from a board is why the company spent a year optimizing for a channel it cannot measure. The reasonable answer, that visibility in AI answers is now the price of entry, is true. It is also not the answer the board asked for.
That is the shape of the 2026 capability gap. The budgets already moved. The channels already shifted. The measurement infrastructure that would let a marketer defend either decision has not caught up, and the organizations that treat that lag as a technical problem to be solved next quarter are the ones that will look back on this year as the moment they got left behind. The ones that treat it as the central problem — ahead of the next channel, ahead of the next tool, ahead of the next reallocation — are the ones that will look back on 2026 as an inflection point.